Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

Revenue Growth 20pctPat Growth 25pctRevenue DeclineEbitda Margin ExpansionResults View source PDF Explain this filing

BLUEJET · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-10.4%Reaction day

₹677.00

prior close

₹672.15

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.7%-9.7% vs market

Pharmaceuticals peers, median of 154sector-0.5%-9.9% vs sector

On the reaction day the stock moved 9.7 pts less than Nifty Smallcap 250 and 9.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.3

10m

-8.5

15m

-8.9

30m

-9.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-10.4-0.7-9.7-0.5-9.9

Next day

-16.8-2.1-14.7-1.6-15.3

-12.3-2.4-10.0-1.9-10.4

-12.7-2.4-10.3-2.4-10.2

-14.3-2.5-11.8-2.9-11.4

-14.2-1.8-12.4-2.0-12.1

-14.9-2.0-12.9-1.7-13.2

15d

-15.8-3.5-12.3-4.0-11.8

-17.4-4.9-12.5-5.2-12.2

-22.3-3.4-18.9-5.5-16.8

-39.0-7.7-31.3-9.9-29.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Blue Jet Healthcare reported H1 FY26 (six months ended Sep 30, 2025) revenue of ₹520.24 crore, up about 40% YoY from ₹371.16 crore. Net profit for H1 FY26 rose roughly 49% YoY (Basic EPS of ₹8.26 vs ₹5.54), with profit before tax of ₹191.59 crore versus ₹126.39 crore. However, the Q2 FY26 (three-month) picture was weaker, with standalone revenue of ₹165.48 crore declining about 20.5% YoY from ₹208.26 crore, reflecting a sharp pullback from the unusually strong Q1 FY26 base of ₹354.76 crore. Operating cash flow jumped to ₹207.19 crore from ₹62.06 crore in H1 FY25, and the company is investing heavily with ₹125.47 crore in capex and capital work-in-progress rising to ₹158.76 crore from ₹88.88 crore. Auditor KKC & Associates issued an unqualified limited review report with no qualifications or emphasis-of-matter paragraphs.

Likely market impact

Strong half-year growth is tempered by a sharp Q2 YoY revenue decline, which could worry investors about demand normalisation after a strong Q1. Healthy cash generation and rising capex suggest management is betting on capacity-led growth, but the Q2 softness may cap near-term upside in the stock.